Drugs / SOT109
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07693751 | Jun 2026 → Nov 2027 expected | colorectal cancer | SOTIO Biotech a.s. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2026-07-14 | SOTIO a.s. | Regulatory FDA Grants Fast Track Designation to SOTIO’s SOT109, a CDH17-targeting ADC for Colorectal Cancer sotio.com ↗ |
| 2025-10-30 | SOTIO a.s. | Results SOTIO to Present Data Highlighting Progress Across ADC and Immunocytokine Programs at Upcoming Scientific Conferences sotio.com ↗
Preclinical findings show robust efficacy and a favorable safety profile, reinforcing best-in-class therapeutic potential. |
| 2025-04-29 | SOTIO a.s. | Results SOTIO Reports Promising Preclinical Data on Antibody-Drug Conjugates SOT109 and SOT106, Underscoring Best-in-Class Potential for Solid Tumor Treatments sotio.com ↗
Preclinical data on SOT109 (anti-CDH17 ADC) and SOT106 (anti-LRRC15 ADC) demonstrate strong anti-tumor activity and favorable tolerability profiles across multiple tumor models, supporting their potential as groundbreaking ADC therapies for various solid tumor types. |
| 2025-03-03 | SOTIO a.s. | Results SOTIO Unveils Promising Preclinical Data on SOT109, a Next-Gen ADC Targeting Cadherin-17 (CDH17) for Colorectal Cancer sotio.com ↗
The data highlight SOT109's promising activity and tolerability profile across multiple disease models, reinforcing its potential to become a best-in-class therapeutic for the treatment of colorectal cancer and other gastrointestinal (GI) cancers. |
All press releases naming this drug 7 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SOT109 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07693751 ↗ |
| Action | Deplete | “designed to find and kill certain cancer cells that carry a marker called CDH17” NCT07693751 ↗ |
| Modality | Monoclonal antibody | “SOT109 is a CDH17-directed monoclonal antibody” NCT07693751 ↗ |
| Target | CDH17 | “SOT109 is a CDH17-directed monoclonal antibody” NCT07693751 ↗ |